Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

Published:2020-07-17 Issue:6 Volume:13 Page:1345-1354
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Yan Xiaoyu¹,Xu Xu Steven²,Weisel Katja C.³⁴,Mateos Maria‐Victoria⁵,Sonneveld Pieter⁶,Dimopoulos Meletios A.⁷,Usmani Saad Zafar⁸,Bahlis Nizar J.⁹,Puchalski Thomas¹⁰,Ukropec Jon¹⁰,Bellew Kevin¹⁰,Ming Qi¹⁰,Sun Steven²,Zhou Honghui¹⁰

Affiliation:

1. Faculty of Medicine School of Pharmacy The Chinese University of Hong Kong Shatin, New Territories Hong Kong SAR Hong Kong

2. Janssen Research and Development Raritan Princeton New Jersey USA

3. Universitätsklinikum Hamburg – Eppendorf II. Medizinische Klinik und Poliklinik Hamburg Germany

4. University of Tuebingen Tuebingen Germany

5. University Hospital of Salamanca–Instituto de Investigación Biomédica de Salamanca (IBSAL) Salamanca Spain

6. Department of Hematology Erasmus Medical Center Rotterdam Netherlands

7. National and Kapodistrian University of Athens School of Medicine Athens Greece

8. Levine Cancer Institute Carolinas HealthCare System Charlotte North Carolina USA

9. Arnie Charbonneau Cancer Institute University of Calgary Tom Baker Cancer Centre Calgary Alberta Canada

10. Janssen Research and Development Spring House Pennsylvania USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12836

Reference37 articles.

1. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

2. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

3. The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

4. Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

5. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving Prediction of Survival and Progression in Metastatic Non–Small Cell Lung Cancer After Immunotherapy Through Machine Learning of Circulating Tumor DNA;JCO Precision Oncology;2024-06

2. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells;Frontiers in Pharmacology;2024-03-04

3. Update on the outcome of M‐protein screening program of multiple myeloma in China: A 7‐year cohort study;Cancer Medicine;2023-12-22

4. Improving prediction of survival and progression in metastatic non-small cell lung cancer following immunotherapy through machine learning of circulating tumor DNA dynamics;2023-10-25

5. Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma;JCO Clinical Cancer Informatics;2023-09